Schedule II & RFK ·
TB-500 (thymosin beta-4 fragment) has a regulatory profile similar to BPC-157 — widely used in research, popular in informal clinical settings, not FDA-approved, and complicated to obtain through US compounding pharmacies after the 2023 bulk substance review. Throughout 2025 and into 2026 the HHS peptide policy discussions have specifically addressed TB-500. RFK Jr.'s stated preference for expanded peptide research access could translate into procedural changes — for example, streamlined IND pathways or expanded 503A bulks nominations — but would not directly change DEA or state-level scheduling. The regulatory status of TB-500 in early 2026 largely mirrors its 2023–2024 status, with evolving discussion but limited formal change.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.